Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection.
A new HPLC method for the simultaneous determination of celecoxib, carboxycelecoxib and hydroxycelecoxib in human plasma samples has been developed. Following a solid-phase extraction procedure, the samples were separated by gradient reversed-phase HLPC (C(18)) and quantified using UV detection at 254 nm. The method was linear over the concentration range 10-500 ng/ml. The intra-assay variability for the three analytes ranged from 4.0 to 12.6% and the inter-assay variability from 4.9 to 14.2%. The achieved limits of quantitation (LOQ) of 10 ng/ml for each analyte allowed the determination of the pharmacokinetic parameters of the analytes after administration of 100 mg celecoxib.
Störmer
Elke
E
Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University Berlin, Schumannstrasse 20/21, 10098, Berlin, Germany. elke.stoermer@charite.de
Bauer
Steffen
S
Kirchheiner
Julia
J
Brockmöller
Jürgen
J
Roots
Ivar
I
D000068579:Celecoxib; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D011720:Pyrazoles; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet / Q000379:methods*; D013449:Sulfonamides / Q000097:blood* / Q000737:chemistry
D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib